SCHEMBL3789047

SCHEMBL3789047

COCCOC1=C(N2CC2)C(=O)C(OCCOC)=C(N2CC2)C1=O

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 2/20 0.35
KDM1A O60341 2/20 0.33
NSD2 O96028 2/20 0.31
TTR P02766 1/20 0.31
P2RY12 Q9H244 1/20 0.31
ALDH1A1 P00352 2/20 0.31
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
CYP1A2 P05177 1/20 0.31
KMT2A Q03164 1/20 0.31
HSD17B10 Q99714 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HTT P42858 1/20 0.31
TIPARP Q7Z3E1 1/20 0.30
PLA2G1B P04054 1/20 0.30
ATG4B Q9Y4P1 1/20 0.30
MAP2K7 O14733 1/20 0.30
CDC25A P30304 1/20 0.30
CDC25B P30305 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Inproquone SCHEMBL2039769 0.82 NSD2 (0.39) TDP2NSD2TTRALDH1A1MEN1
SCHEMBL16225406 0.74 TSHR (0.35) ALDH1A1HSD17B10KDM4EHTTMAP2K7
SCHEMBL16231159 0.73 CDC25A (0.38) ALDH1A1HTTMAP2K7CDC25ACDC25B
SCHEMBL14000306 0.68 TDP2 (0.47) TDP2NSD2ALDH1A1CYP1A2KDM4E
SCHEMBL30825300 0.64 CDC25B (0.56) TDP2ALDH1A1MEN1USP2CYP1A2
SCHEMBL23352271 0.62 KDM1A (0.44) KDM1AALDH1A1MEN1CYP1A2KMT2A
SCHEMBL18591509 0.61 ALDH1A1 (0.39) ALDH1A1CYP1A2HSD17B10KDM4EHTT
SCHEMBL31237648 0.60 MAPT (0.38) TDP2NSD2TTRALDH1A1HTT
SCHEMBL28449439 0.59
SCHEMBL1614158 0.59 HTT (0.42) TDP2NSD2TTRHTTPLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149888-A1 SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS CHEMGENES CORPORATION 2012-06-14 US disclosed
EP-2398815-A2 SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS Chemgenes Corporation (US) 2011-12-28 EP disclosed
WO-2010096201-A2 SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS CHEMGENES CORPORATION (US) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149888-A1 SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS TYMP, MTAP, GART TDP2 314/4885KDM1A 4014/4885NSD2 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.